Trials / Completed
CompletedNCT00171769
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certoparin |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-08-01
- First posted
- 2005-09-15
- Last updated
- 2017-02-23
Locations
2 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00171769. Inclusion in this directory is not an endorsement.